Mitergy Opportunity Identifed by Philadelphia

The Philadelphia office of DFAIT has indentified a partnering opportunity with a PA based company, Mitergy, LLC, www.mitergy.com.

Mitergy, LLC is an early-stage, drug discovery company focused on the progressive cell death that accompanies several human diseases. Diseases with inappropriate cell loss include stroke, progressive heart failure and neurodegenerative diseases such as Parkinson's, Alzheimer's and Amyotropic Lateral Sclerosis (ALS), or Lou Gehrig's Disease. Mitergy's business strategy is predicated on a strong intellectual property position covering a novel disease-related, validated drug target and a new class of therapeutic drugs that prevent cardiomyocyte cell loss due to chemotherapy. Because of the expected involvement of Mitergy's drug target in a variety of end-stage diseases that exhibit accelerated cell loss in affected adult tissues, Mitergy is now poised to form strategic alliances to ensure translation of Mitergy's pre-clinical R&D to meeting the clinical challenge posed by the causative or contributing role premature cell loss in the pathogenesis or progression of human diseases.

In short they are seeking to partner in two areas:

1. New drug development targeting mitochondrial cell death and end-stage pathology for congestive heart failure and ALS.

2. Creation of Predictable drug development animal models for mitochondrial pathology, in particular for Parkinson's Disease